TECENTRIQ 60 mg/ml Concentrate For Solution For Infusion 60 mg/ml Injection 20ml Vial
First reference:
TECENTRIQ (Atezolizumab) 60 mg/ml Concentrate For Solution For Infusion
TECENTRIQ (Atezolizumab) is an advanced immunotherapy medication designed to treat various types of cancer.
It is a monoclonal antibody that targets the PD-L1 protein found on cancer cells and immune cells.
By blocking PD-L1, TECENTRIQ helps to unleash the immune system's ability to detect and fight cancer cells.
This medication is administered intravenously by healthcare professionals in a clinical setting.
Benefits of Use:
TECENTRIQ is indicated for the treatment of various cancers, including:
- Non-small cell lung cancer (NSCLC)
- Small cell lung cancer (SCLC)
- Urothelial carcinoma (a type of bladder cancer)
- Hepatocellular carcinoma (a type of liver cancer)
- Triple-negative breast cancer (TNBC)
It works by enhancing the body's natural immune response against cancer, potentially leading to tumor shrinkage and improved survival rates in eligible patients.
How to Use:
TECENTRIQ is a prescription medication administered by a healthcare professional.
- TECENTRIQ is given as an intravenous (IV) infusion into a vein, typically over 30 to 60 minutes.
- The specific dose and frequency of administration will be determined by your doctor based on your type of cancer, body weight, and response to treatment.
- It is crucial to follow your doctor's instructions precisely regarding treatment schedule and dosage.
- Do not attempt to self-administer this medication.
Caution & Warnings:
Immune-related Adverse Reactions: TECENTRIQ can cause serious side effects that result from an overactive immune system attacking healthy organs. These can include inflammation of the lungs (pneumonitis), liver (hepatitis), colon (colitis), hormone-producing glands (endocrinopathies), and other organs. Report any new or worsening symptoms to your doctor immediately.
Infusion-related Reactions: Some patients may experience infusion-related reactions, such as fever, chills, flushing, rash, or shortness of breath. These reactions are typically managed by the healthcare team.
Pregnancy and Lactation: TECENTRIQ can harm an unborn baby. Women of childbearing potential should use effective contraception during treatment and for at least 5 months after the last dose. It is not known if TECENTRIQ passes into breast milk, so breastfeeding is not recommended during treatment.
Driving and Operating Machinery: Fatigue or other side effects may affect your ability to drive or operate machinery. Exercise caution until you know how TECENTRIQ affects you.
Interactions: Inform your doctor about all medications, supplements, and herbal products you are taking to avoid potential interactions.
Ingredients:
Active Ingredient: Atezolizumab
Excipients: L-histidine, acetic acid, sucrose, polysorbate 20, and water for injection.
Product Details:
- Product Name: TECENTRIQ 60 mg/ml Concentrate For Solution For Infusion
- Strength: 60 mg/ml
- Volume: 20ml per vial
- Total Drug Content per Vial: 1200 mg Atezolizumab
- Manufacturer: Roche
- Form: Concentrate for solution for infusion
- Administration: Intravenous
- Storage: Store in a refrigerator (2°C to 8°C). Do not freeze. Keep in original carton to protect from light.
| Gtin | 07613326000413 |
|---|---|
| Recommended Sale Price | 29065.25 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | ATEZOLIZUMAB |
| SFDA Reg. No | 285-24-17 |
| IBC | 07613326000413 |
| Drug Type | Prescription |
| Scientific Name | Atezolizumab |
| Strength | 60 mg/ml |
| Strength Unit | mg/ml |
| Form | Concentrate for solution for infusion |
| Admin Route | Intravenous |
| Size | 20 |
| Size Unit | ml |
| Package Types | Vial |
| Package Size | 20ml |
| Storage conditions | Store in a refrigerator (2°C to 8°C). Do not freeze. Keep the vial in the outer carton to protect from light. |
| Refrigerator Storage | Yes |
